Placebo Control

(*For certain possibly nonstandard uses of the word "unpublished") This is an odd little study. Instead of looking at registere...

Results reporting requirements are pretty clear. Maybe critics should re-check their methods? Ben Goldacre has rather famously described t...

No stones, please. Yesterday, Alec Gaffney was kind enough to ask my opinion on GSK's signing on to the AllTrials initiative to b...

Ben Goldacre – whose Bad Pharma went on sale today – is fond of using a coin-toss-cheating analogy to describe the problem of "hidde...

Placebo Control is going purple today in support of Alzheimer’s Action Day . A couple of clinical trial related thoughts on the ongoing st...

I have a lot of respect for Eric Topol, and am a huge fan of his ongoing work  to bring new mobile technology to benefit patients. The ...

* for some value of "most" ** for some value of "too" [Note: this is a companion to a previous post, Clouding the Deba...

A quick update on my last post regarding the enormously controversial -- but completely unmentioned -- requirement to publicly report all v...

Not to be confused with the Test Act . (via Luminarium) 4 Democratic members of Congress recently co-sponsored the TEST (Trial and Expe...

A few years back, I was working with a small biotech companies as they were ramping up to begin their first-ever pivotal trial. One of the ...